This is a short term win, no 2 ways about it. His rep & contacts with the NIH, previous dialogue with the FDA, overall HIV experience, and scientific expertise (garner respect w/ FDA) as well as age (never hurts to have a more seasoned person at the helm when dealing with other seasoned folks at gov agencies and/or being able to navigate the younger ones who should in theory respect him) - all big wins to get us from point a to point b with a longer term CEO afterwards for business reasons once major hurdles are overcome. Best piece of news in a long long time imo.